Converting a peptide into a drug: strategies to improve stability and bioavailability.
about
Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraintsFangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processingPEPlife: A Repository of the Half-life of PeptidesDirect Activation of Bax Protein for Cancer TherapyForcefield_NCAA: ab initio charge parameters to aid in the discovery and design of therapeutic proteins and peptides with unnatural amino acids and their application to complement inhibitors of the compstatin family.Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery.Solution phase conformation and proteolytic stability of amide-linked neuraminic acid analogues.Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification.The energy landscape of a selective tumor-homing pentapeptideFunctional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.Perspectives for clinical use of engineered human host defense antimicrobial peptidesComparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607.NCAD, a database integrating the intrinsic conformational preferences of non-coded amino acids.Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments.A straightforward route to enantiopure alpha-substituted derivatives of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid.Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII.Peptides for therapy and diagnosis of Alzheimer's disease.In vitro selection of highly modified cyclic peptides that act as tight binding inhibitors.Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1.Immunity and behavior: antibodies alter emotionQuorumpeps database: chemical space, microbial origin and functionality of quorum sensing peptides.Versatile methodology for the synthesis and α-functionalization of (2R,3aS,7aS)-octahydroindole-2-carboxylic acidPhage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication.Conformational profile of a proline-arginine hybrid.Feasibility of β-sheet breaker peptide-H102 treatment for Alzheimer's disease based on β-amyloid hypothesis.A novel peptide (Thx) homing to non-small cell lung cancer identified by ex vivo phage display.Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell culturesOvine colostrum nanopeptide affects amyloid beta aggregation.The TLQP-21 peptide activates the G-protein-coupled receptor C3aR1 via a folding-upon-binding mechanismLatest approaches for efficient protein production in drug discovery.Feleucin-BO1: a novel antimicrobial non-apeptide amide from the skin secretion of the toad, Bombina orientalis, and design of a potent broad-spectrum synthetic analogue, feleucin-K3.A simple protocol for combinatorial cyclic depsipeptide libraries sequencing by matrix-assisted laser desorption/ionisation mass spectrometry.Library construction, selection and modification strategies to generate therapeutic peptide-based modulators of protein-protein interactions.Biosynthesis and antimicrobial evaluation of backbone-cyclized α-defensinsThe remarkable stability of chimeric, sialic acid-derived alpha/delta-peptides in human blood plasma.Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity.Classification of scaffold-hopping approachesDeciphering Mode of Action of Functionally Important Regions in the Intrinsically Disordered Paxillin (Residues 1-313) Using Its Interaction with FAT (Focal Adhesion Targeting Domain of Focal Adhesion Kinase).Novel dipeptide nanoparticles for effective curcumin delivery
P2860
Q27021652-828DD23A-7BE2-458D-A371-006AF115D434Q28480389-EA3DA6B7-E24E-4F03-B378-DF314E36AD64Q28821997-7BD31E41-EB04-4CA1-BDDC-0B0231756682Q30353924-3CE4AF60-1323-4AF1-A40A-F5A5703452BDQ30363657-3DAD0ABA-C1BC-4DDB-ADBE-D69B51B3E672Q30381745-390EC46E-D81E-45FC-BF0F-2F2D966CE53CQ30391507-4C663BE9-B841-496B-B6EA-07A0C7B64156Q30647857-9A0B7DB1-DC58-4DFD-A141-A3C98DCA64C0Q30855629-E522F49A-5579-4BAC-9371-1586510801C6Q33347507-827465E0-5218-41DF-B915-476B720C5438Q33635059-01637869-7EF4-4025-B88F-CC8BDCFDB918Q33700825-519AC5DE-0C3B-4D5B-97FC-B6E4952B02DFQ33884461-3C5D7BD4-5FC1-4104-89BF-923985491A35Q33961066-D443F581-C755-4D1E-BFE6-09E9E3558C9AQ33975429-6C850968-B1D4-4E4C-B445-4E1F7500B7FEQ33997415-1AC3BE5A-764F-4993-BA1E-312988506864Q34048086-8B8451F6-C6F4-4E2B-AC84-FB57E7A27BEDQ34124260-BE9CB2E1-1BE3-43A3-9F7D-82E503D4E58FQ34201330-771B2A11-2F0B-4FF2-9376-B0C9944CE780Q34262850-CB7478BF-DD24-4877-9A12-4E78E4BFE7B3Q34270963-A331B8DD-6D73-44AE-95C7-57DF8684745AQ34313705-C7F12019-70EE-4214-9A9F-C79ED3BFC5B3Q34347053-BB6F9C07-A29B-47BE-A3EC-0F8F6C7C5C09Q34350400-AA7FA1D1-E4D0-4E65-9890-42E66F2C9BBEQ34384961-ABA19DD7-AB52-4745-B73F-BC3C8ACAB5B4Q34457296-AF4727D7-96DC-473C-A04E-C90D0FE3BB8BQ34473561-91904941-7807-45C4-8195-BB409D2D7EEFQ34548310-CF05AB1B-7A22-45E9-9D2A-AF3F167D9D38Q34904386-86116F05-076B-41FE-83A0-29204A4755C5Q35159111-62DA64C7-AE9A-4B94-A125-FB8CF87B06E8Q35209937-FD32C9AD-BE66-42AC-A45C-0CE3812791ABQ35212120-10510194-1914-4D4E-8564-75BDC89CE20EQ35446970-7A65330C-C255-4083-9540-C7A10048EDECQ35532355-72517274-0138-4C6D-B294-9682508A7651Q35610217-2C04F760-BB5B-4173-A335-0852791F1DAFQ35857076-7BEA3046-1DD4-49B7-AB2D-D31F98245132Q35871913-89234BAF-A3DE-40F5-AC6C-0A44F5B051B5Q35893996-6DB5E433-9B67-4753-819B-6501B3E5CECFQ35940252-AD9F9754-9C1A-4F58-8A73-3BD10049E481Q36161136-41BF7FE6-7306-4F9B-B14B-9E5BBE3546CA
P2860
Converting a peptide into a drug: strategies to improve stability and bioavailability.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Converting a peptide into a drug: strategies to improve stability and bioavailability.
@ast
Converting a peptide into a drug: strategies to improve stability and bioavailability.
@en
Converting a peptide into a drug: strategies to improve stability and bioavailability.
@nl
type
label
Converting a peptide into a drug: strategies to improve stability and bioavailability.
@ast
Converting a peptide into a drug: strategies to improve stability and bioavailability.
@en
Converting a peptide into a drug: strategies to improve stability and bioavailability.
@nl
prefLabel
Converting a peptide into a drug: strategies to improve stability and bioavailability.
@ast
Converting a peptide into a drug: strategies to improve stability and bioavailability.
@en
Converting a peptide into a drug: strategies to improve stability and bioavailability.
@nl
P356
P1476
Converting a peptide into a drug: strategies to improve stability and bioavailability.
@en
P2093
Celine Adessi
Claudio Soto
P304
P356
10.2174/0929867024606731
P577
2002-05-01T00:00:00Z